Abstract
The capacity of DNA to bind RNA via Watson-Crick base-pairing is fundamental to antisense oligonucleotide strategies to inhibit gene expression, and is a property that has been exploited by bioengineers in the generation of catalytic molecules such as ribozymes, ribozyme subtypes, and more recently DNAzymes. This review describes the evolution of these gene-specific agents and summarizes recent efforts to inhibit smooth muscle cell growth with these molecules as candidate therapeutic tools in restenosis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Base Pairing
-
Coronary Restenosis / genetics
-
Coronary Restenosis / prevention & control*
-
DNA / genetics
-
DNA, Catalytic / genetics
-
DNA, Catalytic / therapeutic use
-
DNA, Single-Stranded / genetics
-
DNA, Single-Stranded / therapeutic use
-
Gene Expression Regulation*
-
Gene Targeting
-
Humans
-
Muscle, Smooth, Vascular / physiology
-
Nucleic Acids / genetics*
-
Oligodeoxyribonucleotides, Antisense / genetics*
-
Oligodeoxyribonucleotides, Antisense / therapeutic use*
-
RNA / genetics
-
RNA, Catalytic / genetics
-
RNA, Catalytic / therapeutic use
Substances
-
DNA, Catalytic
-
DNA, Single-Stranded
-
Nucleic Acids
-
Oligodeoxyribonucleotides, Antisense
-
RNA, Catalytic
-
RNA-cleaving DNA 10-23
-
RNA
-
DNA